BioNTech Q2 2026 Earnings: Lower COVID Vaccine Demand Deepens Losses

BioNTech (Nasdaq: BNTX) reported Q2 2026 revenue of €105.6 million, down approximately 59.5% from €260.8 million a year earlier, while IFRS diluted EPS was a loss of €3.24 versus a loss of €1.60. The IFRS net loss widened to €820.8 million as lower COVID-19 vaccine revenue coincided with higher research, administrative and pipeline-prioritization costs, although quarterly operating cash flow remained positive at €10.5 million.

Core Financial Results

Revenue declined primarily because of lower demand for BioNTech’s COVID-19 vaccines. Cost of sales nevertheless increased to €97.0 million from €76.4 million, reducing calculated gross profit to approximately €8.6 million and leaving the quarterly cost base high relative to revenue.

Gross profit and gross margin are approximate calculations based on reported revenue and cost of sales. BioNTech’s adjusted figures are non-IFRS measures and exclude specified impairment and employee-related restructuring effects.

Business and Pipeline Performance

The commercial business remained affected by declining COVID-19 vaccine demand. BioNTech and Pfizer submitted applications for their XFG-adapted monovalent vaccine for the 2026–2027 season, and the European Commission authorized the vaccine in July 2026, after the quarter ended. Preparations for additional launches were underway in line with recommendations from relevant authorities.

Oncology development continued to expand, with 14 ongoing registrational studies and six such trials initiated during 2026 by the reporting date. Five of the new studies involved Pumitamig, while one evaluated the B7-H3-directed antibody-drug conjugate Elfetabart Drozuntecan.

Pumitamig was being studied in seven registrational trials. The Phase 3 portion of ROSETTA Lung-02 was recruiting patients, while Phase 2 data presented at ASCO showed what the company described as encouraging activity across PD-L1 expression levels and both squamous and non-squamous non-small cell lung cancer.

Other late-stage programs also advanced. A non-registrational dose-finding stage of the Gotistobart Phase 3 program reported a 0.46 overall-survival hazard ratio against standard chemotherapy. BioNTech also started a Phase 3 study of Elfetabart Drozuntecan in metastatic castration-resistant prostate cancer and, subject to regulatory feedback, planned a 2026 biologics license application involving Trastuzumab Pamirtecan.

Separately, BioNTech appointed Guido Oelkers as its next CEO. He is expected to take office by February 1, 2027, succeeding co-founder Ugur Sahin.

Lower Vaccine Revenue and Pipeline-Prioritization Charges Widened Losses

The central financial issue was that expenses did not decline with revenue. IFRS research and development expense increased approximately 8.2% to €551.0 million, driven by higher spending on immuno-oncology and antibody-drug conjugate programs—particularly Pumitamig and Gotistobart—along with intangible-asset impairments and the inclusion of CureVac operations. Lower spending on non-priority programs and partner cost-sharing provided partial offsets.

Adjusted R&D expense, which excluded €73.9 million of impairment charges, declined approximately 6.3% to €477.1 million. This difference shows that part of the IFRS increase was non-cash, but underlying operating pressure remained because revenue fell faster than adjusted spending.

Selling and general administrative expense increased approximately 44.0% to €197.8 million. BioNTech attributed the increase to building commercial infrastructure, including CureVac’s operations, and spending on process and enterprise resource planning systems. Pipeline-prioritization initiatives and cost discipline offset part of the increase.

Other operating results were a negative €207.9 million, compared with a negative €39.0 million a year earlier, mainly because of pipeline-prioritization expenses. The €258.5 million difference between IFRS and adjusted quarterly net loss reflected €160.9 million of impairment adjustments and €97.6 million of employee-related restructuring adjustments.

Cash Flow and Balance Sheet

Quarterly operating cash flow remained positive despite the €820.8 million net loss. The reconciliation included €266.1 million of depreciation and impairment, a €366.0 million decrease in receivables, contract assets and other assets, and a €224.7 million increase in liabilities and provisions. These non-cash and working-capital effects explain much of the gap between accounting losses and quarterly cash flow.

The first-half picture was weaker but improved year over year: operating cash flow was negative €410.5 million for the six months ended June 30, compared with negative €634.2 million in the prior-year period.

BioNTech ended June with €16.63 billion in cash, cash equivalents and liquid securities. This included €9.74 billion of cash and cash equivalents, €5.04 billion of short-term liquid securities and €1.86 billion of long-term liquid securities.

The company also repurchased 1,693,056 American depositary shares during the quarter at an average price of $89.50, spending $151.6 million, or €131.8 million. The broader authorization allows repurchases of up to $1.0 billion through May 6, 2027.

Full-Year Guidance

BioNTech lowered both ends of its 2026 revenue outlook by €400 million and reduced both ends of its adjusted R&D expense range by €200 million. Adjusted selling and administrative expense guidance was unchanged.

The revenue reduction reflected lower-than-expected global COVID-19 vaccine demand, the planned use of existing vaccine inventory in Germany during the 2026 vaccination season, and milestone revenue from an out-licensed R&D program that was no longer expected in 2026. BioNTech continued to expect most annual revenue in the second half, including recognition of €613 million from its Bristol Myers Squibb collaboration in the third quarter.

Recent Insider Transactions

The supplied insider dataset contains one dated transaction in its two-year table. It also reports zero purchases and zero sales in a separate six-month aggregate, making the two supplied summaries internally inconsistent.

The transaction is presented as reported without drawing a conclusion about management’s view of the company.

Risks Investors Need to Watch

• Continued weakness in COVID-19 vaccine demand: Lower global demand was the main reason for the quarterly revenue decline and the reduced full-year outlook. Additional demand weakness could further affect revenue and gross profit.
• Revenue timing and concentration: BioNTech expects most 2026 revenue in the second half, including €613 million of BMS collaboration revenue in Q3. Milestone-related revenue can shift between periods, as shown by the out-licensed program payment no longer expected this year.
• Limited gross-margin visibility: Cost of sales increased even as quarterly revenue fell, reducing calculated gross margin to approximately 8.1%. The release did not provide a specific explanation for the higher quarterly cost of sales.
• Clinical and regulatory execution: BioNTech’s oncology strategy depends on results from 14 registrational studies, upcoming late-stage data and potential regulatory filings. Clinical timelines, outcomes and approvals remain uncertain.
• Sustained spending and cash use: The balance sheet remains substantial, but first-half operating cash flow was negative and BioNTech continues to fund late-stage trials, commercial infrastructure and integration-related activities while reporting significant losses.

Summary

BioNTech’s second quarter reflected the continuing transition from COVID-19 vaccine dependence toward a broader oncology portfolio. Lower vaccine demand and a high development and administrative cost base widened both IFRS and adjusted losses, while working-capital and non-cash effects kept quarterly operating cash flow slightly positive. The main items to monitor are execution of the revised revenue outlook, recognition of second-half collaboration revenue, expense discipline and data from the company’s expanding late-stage oncology pipeline.